期刊
CANCER DISCOVERY
卷 4, 期 7, 页码 766-772出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-14-0196
关键词
-
类别
资金
- NIH [R37 CA53370, RC1 CA147961, R01 CA163591, R01 CA130893]
- Department of Defense [W81XWH-09-01-0394]
- Val Skinner Foundation
- New Jersey Commission on Cancer Research [09-2406-CCR-E0]
- Rutgers Cancer Institute of New Jersey [P30 CA072720]
Metabolomic analyses of human tumors and mouse models of cancer have identified key roles for autophagy in supporting mitochondrial metabolism and homeostasis. In this review, we highlight data suggesting that autophagy inhibition may be particularly effective in BRAF-driven malignancies. Catalytic BRAF inhibitors have profound efficacy in tumors carrying activating mutations in Braf but are limited by the rapid emergence of resistance due in part to increased mitochondrial biogenesis and heightened rates of oxidative phosphorylation. We suggest that combined inhibition of autophagy and BRAF may overcome this limitation. Significance: Braf(V600E)-driven tumors require autophagy and likely autophagy-provided substrates to maintain mitochondrial metabolism and to promote tumor growth, suggesting that autophagy ablation may improve cancer therapy. (C) 2014 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据